ATE468853T1 - Substituierte pyrazole, derartige verbindungen enthaltende zusammensetzungen und verfahren zu ihrer verwendung - Google Patents
Substituierte pyrazole, derartige verbindungen enthaltende zusammensetzungen und verfahren zu ihrer verwendungInfo
- Publication number
- ATE468853T1 ATE468853T1 AT05773502T AT05773502T ATE468853T1 AT E468853 T1 ATE468853 T1 AT E468853T1 AT 05773502 T AT05773502 T AT 05773502T AT 05773502 T AT05773502 T AT 05773502T AT E468853 T1 ATE468853 T1 AT E468853T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- methods
- compositions containing
- substituted pyrazoles
- pyrazoles
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000000203 mixture Chemical class 0.000 title abstract 2
- 150000003217 pyrazoles Chemical class 0.000 title abstract 2
- 229940122904 Glucagon receptor antagonist Drugs 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59017204P | 2004-07-22 | 2004-07-22 | |
| PCT/US2005/025541 WO2006014618A2 (en) | 2004-07-22 | 2005-07-19 | Substituted pyrazoles, compositions containing such compounds and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE468853T1 true ATE468853T1 (de) | 2010-06-15 |
Family
ID=35787673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05773502T ATE468853T1 (de) | 2004-07-22 | 2005-07-19 | Substituierte pyrazole, derartige verbindungen enthaltende zusammensetzungen und verfahren zu ihrer verwendung |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7625938B2 (de) |
| EP (1) | EP1773330B1 (de) |
| JP (1) | JP2008507528A (de) |
| CN (1) | CN1993124A (de) |
| AT (1) | ATE468853T1 (de) |
| AU (1) | AU2005269792B9 (de) |
| CA (1) | CA2574147A1 (de) |
| DE (1) | DE602005021494D1 (de) |
| WO (1) | WO2006014618A2 (de) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7572922B2 (en) * | 2003-01-27 | 2009-08-11 | Merck & Co., Inc. | Substituted pyrazoles, compositions containing such compounds and methods of use |
| DE602005006806D1 (de) * | 2004-06-04 | 2008-06-26 | Merck & Co Inc | Pyrazolderivate, zusammensetzungen, die solche verbindungen enthalten, und anwendungsverfahren |
| US8318760B2 (en) * | 2005-03-21 | 2012-11-27 | Merck Sharp & Dohme Corp. | Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use |
| TW200720254A (en) * | 2005-04-07 | 2007-06-01 | Nippon Kayaku Kk | Use of 3,5-diphenyl pyrazole derivatives as anti-tumor agent |
| KR20190126460A (ko) | 2007-02-09 | 2019-11-11 | 메타베이시스 테라퓨틱스, 인크. | 글루카곤 수용체의 길항제 |
| GEP20135844B (en) * | 2008-03-05 | 2013-06-10 | Takeda Pharmaceutical | Heterocyclic compound |
| EP2291358B1 (de) * | 2008-05-16 | 2018-03-28 | Merck Sharp & Dohme Corp. | Glucagonrezeptorantagonisten, zusammensetzungen und verfahren zu ihrer verwendung |
| EP2805939B1 (de) * | 2008-05-19 | 2018-06-27 | Merck Sharp & Dohme Corp. | Heterocyclische Verbindungen als Faktor-IXA-Inhibitoren |
| AU2009272033B2 (en) * | 2008-07-17 | 2011-10-13 | Asahi Kasei Pharma Corporation | Nitrogenated heterocyclic compound |
| CA2770298C (en) | 2008-08-13 | 2017-06-20 | Metabasis Therapeutics, Inc. | Glucagon antagonists |
| EP2330894B8 (de) | 2008-09-03 | 2017-04-19 | BioMarin Pharmaceutical Inc. | Zusammensetzungen mit 6-aminohexansäurederivaten als hdac-hemmer |
| EP2346830B1 (de) * | 2008-09-15 | 2015-05-13 | Merck Sharp & Dohme Corp. | Den glucagonrezeptor antagonisierende verbindungen, zusammensetzungen, die solche verbindungen enthalten, und anwendungsverfahren |
| EP2350020B1 (de) * | 2008-10-03 | 2014-08-13 | Merck Sharp & Dohme Corp. | Spiro-imidazolonderivate als glucagonrezeptorantagonisten |
| US8324384B2 (en) | 2009-02-12 | 2012-12-04 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| US8318667B2 (en) | 2009-02-25 | 2012-11-27 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| WO2010144664A1 (en) * | 2009-06-12 | 2010-12-16 | Schering Corporation | Thiophenes as glucagon receptor antagonists, compositions, and methods for their use |
| US8735604B2 (en) | 2009-09-22 | 2014-05-27 | Merck Sharp & Dohme Corp. | Pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use |
| JP5568277B2 (ja) * | 2009-10-22 | 2014-08-06 | 株式会社日立ハイテクノロジーズ | パターンマッチング方法、及びパターンマッチング装置 |
| MX2013006768A (es) | 2010-12-23 | 2013-07-22 | Pfizer | Moduladores de receptor de glucagon. |
| HRP20161177T1 (hr) | 2011-02-08 | 2016-11-04 | Pfizer Inc. | Modulator glukagonskog receptora |
| US9540395B2 (en) | 2011-02-28 | 2017-01-10 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
| US8957066B2 (en) | 2011-02-28 | 2015-02-17 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
| US10059723B2 (en) | 2011-02-28 | 2018-08-28 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
| AU2012288493B2 (en) * | 2011-07-22 | 2015-08-06 | Pfizer Inc. | Quinolinyl glucagon receptor modulators |
| TW201427658A (zh) | 2012-12-10 | 2014-07-16 | Merck Sharp & Dohme | 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法 |
| WO2014143666A1 (en) | 2013-03-15 | 2014-09-18 | Biomarin Pharmaceutical Inc. | Hdac inhibitors |
| EP3065736B1 (de) | 2013-11-04 | 2018-11-14 | Merck Sharp & Dohme Corp. | Glucagon-rezeptor-antagonist-verbindungen, zusammensetzungen daraus und verfahren zur verwendung |
| WO2015191900A1 (en) | 2014-06-12 | 2015-12-17 | Ligand Pharmaceuticals, Inc. | Glucagon antagonists |
| MA46089A (fr) | 2016-08-30 | 2019-07-10 | Regeneron Pharma | Procédés de traitement de la résistance à l'insuline grave par interférence avec la signalisation du récepteur du glucagon |
| US20190248888A1 (en) | 2016-10-20 | 2019-08-15 | Regeneron Pharmaceuticals, Inc. | Methods of lowering blood glucose levels |
| CA3071387A1 (en) | 2017-08-22 | 2019-02-28 | Regeneron Pharmaceuticals, Inc. | Methods of treating urea cycle disorders by interfering with glucagon receptor signaling |
| WO2019160940A1 (en) | 2018-02-13 | 2019-08-22 | Ligand Pharmaceuticals Incorporated | Glucagon receptor antagonists |
| CN114276338B (zh) * | 2022-01-06 | 2023-11-28 | 苏州大学 | 2-吡唑-3-苯并咪唑衍生物及其制备方法和应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0859771A4 (de) | 1995-10-31 | 2000-03-15 | Merck & Co Inc | Substituierte pyridylpyrrole, solche verbindungen enthaltende zubereitungen und verfahren zu deren nutzung |
| AR008789A1 (es) | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
| US5776954A (en) | 1996-10-30 | 1998-07-07 | Merck & Co., Inc. | Substituted pyridyl pyrroles, compositions containing such compounds and methods of use |
| WO1998021957A1 (en) | 1996-11-20 | 1998-05-28 | Merck & Co., Inc. | Triaryl substituted imidazoles, compositions containing such compounds and methods of use |
| WO1998022109A1 (en) | 1996-11-20 | 1998-05-28 | Merck & Co., Inc. | Triaryl substituted imidazoles as glucagon antagonists |
| EP0959885A4 (de) | 1996-11-20 | 2002-07-17 | Merck & Co Inc | Triaryl substituierte imidazole und verfahren zur verwendung |
| US6613942B1 (en) | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| US6503949B1 (en) | 1999-05-17 | 2003-01-07 | Noro Nordisk A/S | Glucagon antagonists/inverse agonists |
| MXPA02001393A (es) | 1999-08-10 | 2002-08-12 | Bayer Agrochem Kk | Herbicidas derivados de tetrazolinona. |
| US6562807B2 (en) | 2000-06-23 | 2003-05-13 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| WO2002008188A1 (en) | 2000-07-25 | 2002-01-31 | Merck & Co., Inc. | N-substituted indoles useful in the treatment of diabetes |
| US20030203946A1 (en) | 2000-11-17 | 2003-10-30 | Carsten Behrens | Glucagon antagonists/inverse agonists |
| AU2002223501A1 (en) | 2000-11-17 | 2002-05-27 | Agouron Pharmaceuticals, Inc. | Glucagon antagonists/inverse agonists |
| DE10122716A1 (de) * | 2001-05-10 | 2002-11-14 | Baeuerle Gmbh Mathias | Transporteinrichtung für flaches Transportgut, vorzugsweise Papier |
| US6762318B2 (en) | 2001-12-03 | 2004-07-13 | Novo Nordisk A/S | Glucagon antagonists |
| US6881746B2 (en) | 2001-12-03 | 2005-04-19 | Novo Nordick A/S | Glucagon antagonists/inverse agonists |
| AU2002351730A1 (en) | 2001-12-19 | 2003-06-30 | Novo Nordisk A/S | Glucagon receptor antagonists/inverse agonists |
| WO2003053938A1 (en) | 2001-12-20 | 2003-07-03 | Novo Nordisk A/S | Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten |
| TWI262917B (en) | 2002-02-01 | 2006-10-01 | Dainippon Sumitomo Pharma Co | 2-Furancarboxylic hydrazides and pharmaceutical compositions containing the same |
| AU2003233780A1 (en) | 2002-06-27 | 2004-01-19 | Novo Nordisk A/S | Novel glucagon antagonists/inverse agonists |
| EP1523350B1 (de) | 2002-07-19 | 2011-04-13 | Baxter International Inc. | System für die peritonealdialyse |
| WO2004050039A2 (en) | 2002-12-04 | 2004-06-17 | Merck & Co., Inc. | Spirocyclic ureas, compositions containing such compounds and methods of use |
| US7572922B2 (en) * | 2003-01-27 | 2009-08-11 | Merck & Co., Inc. | Substituted pyrazoles, compositions containing such compounds and methods of use |
| BRPI0409447A (pt) | 2003-04-14 | 2006-04-18 | Inst For Pharm Discovery Inc | ácidos fenilalcanóicos substituìdos |
| AU2004238240A1 (en) | 2003-05-09 | 2004-11-25 | Merck & Co., Inc. | Benzimidazoles, compositions containing such compounds and methods of use |
| DE602005006806D1 (de) | 2004-06-04 | 2008-06-26 | Merck & Co Inc | Pyrazolderivate, zusammensetzungen, die solche verbindungen enthalten, und anwendungsverfahren |
| AR056574A1 (es) | 2005-10-19 | 2007-10-10 | Merck & Co Inc | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso |
-
2005
- 2005-07-19 US US11/632,198 patent/US7625938B2/en active Active
- 2005-07-19 CA CA002574147A patent/CA2574147A1/en not_active Abandoned
- 2005-07-19 AT AT05773502T patent/ATE468853T1/de not_active IP Right Cessation
- 2005-07-19 AU AU2005269792A patent/AU2005269792B9/en not_active Ceased
- 2005-07-19 DE DE602005021494T patent/DE602005021494D1/de not_active Expired - Lifetime
- 2005-07-19 EP EP05773502A patent/EP1773330B1/de not_active Expired - Lifetime
- 2005-07-19 WO PCT/US2005/025541 patent/WO2006014618A2/en not_active Ceased
- 2005-07-19 CN CNA2005800246617A patent/CN1993124A/zh active Pending
- 2005-07-19 JP JP2007522643A patent/JP2008507528A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005269792A1 (en) | 2006-02-09 |
| EP1773330A4 (de) | 2009-01-21 |
| WO2006014618A3 (en) | 2006-10-19 |
| CA2574147A1 (en) | 2006-02-09 |
| AU2005269792B2 (en) | 2008-07-03 |
| EP1773330A2 (de) | 2007-04-18 |
| WO2006014618A2 (en) | 2006-02-09 |
| EP1773330B1 (de) | 2010-05-26 |
| US7625938B2 (en) | 2009-12-01 |
| US20080108620A1 (en) | 2008-05-08 |
| AU2005269792B9 (en) | 2008-11-27 |
| JP2008507528A (ja) | 2008-03-13 |
| DE602005021494D1 (de) | 2010-07-08 |
| CN1993124A (zh) | 2007-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE468853T1 (de) | Substituierte pyrazole, derartige verbindungen enthaltende zusammensetzungen und verfahren zu ihrer verwendung | |
| ATE490244T1 (de) | Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren | |
| WO2004100875A3 (en) | Benzimidazoles, compositions containing such compounds and methods of use | |
| UA96308C2 (ru) | Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение | |
| TW200745031A (en) | Acyl indoles, compositions containing such compounds and methods of use | |
| WO2007111864A3 (en) | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | |
| WO2007136577A3 (en) | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | |
| WO2006104826A3 (en) | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | |
| WO2004050039A3 (en) | Spirocyclic ureas, compositions containing such compounds and methods of use | |
| ATE435210T1 (de) | Tetrahydroisochinolylacetamidderivate zur verwendung als orexinrezeptorantagonisten | |
| MY143599A (en) | Pyrazole derivatives, compositions containing such compounds and methods of use | |
| MXPA04000707A (es) | Nuevos antagonistas del receptor y5 del neuropeptido y referencia cruzada a solicitudes relacionadas. | |
| ATE538650T1 (de) | Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht | |
| DE60212801D1 (de) | Verwendung azetidinone-substituierter verbindungen zur behandlung der sitosterolhämie | |
| WO2005089118A3 (en) | Novel bicyclic compounds as modulators of androgen receptor function and method | |
| GEP20125565B (en) | Lactam compounds and their pharmaceutical use | |
| EA200601555A1 (ru) | Замещенные индазол-о-глюкозиды | |
| ATE532781T1 (de) | 5-(acylamino)indazol-derivate als kinase- inhibitoren | |
| ATE449604T1 (de) | Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren | |
| NO20076515L (no) | Hydantoinforbindelser | |
| NO20064325L (no) | Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes | |
| WO2005060959A8 (en) | Pyrazole derivatives and use thereof as orexin receptor antagonists | |
| EP1398029A8 (de) | 3-substituierte Pyrazol-Derivate,die an den NR3B1 Rezeptor binden | |
| ATE421519T1 (de) | Substituierte bizyklische thiophen-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren | |
| TW200745044A (en) | Pyrazole derivatives, compositions containing such compounds and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |